@Goodell_Lab

The Goodell Lab. Hematopoietic stem cells, epigenetics, DNA methylation. Chair, Dept of Mol Cell Biology at Baylor College of Medicine. Tweets my own.

Houston, Texas
Joined March 2012
I had an incredible opportunity to talk with Dr. Tolar, the President of BCM, about my research, my involvement with the Postdoctoral Association, and my experience at BCM and in the @Goodell_Lab. As always, feeling more comfortable pipetting than talking.
BCM News with Dr. Tolar and his guest today, Dr. E. Khabusheva @sciencyelmira, a #BCMpostdoc studying #AML in @Goodell_Lab Sept. 25, 2026 #PAW26 youtu.be/JMXelEOvB7o?si=R6qy… via @YouTube
2
6
657
Well, who is curious? How did Stella Trout do in her #Jeopardy! Champions Wild Card quarterfinals game? Did she make it to Final Jeopardy in good standing? Was she confident enough in the #Science category to wager big? Did she answer the #Biology question right?
7
1
1
52
4,507
Jeopardy! Champion Stella Trout in the nail-biters of the Champions Wild Card (CWC) Tournament- reruns this week and next! Definitely smarter than her mom! Going to the TOC this year! instagram.com/reel/DbWBv5vj-…
1
162
Peggy Goodell retweeted
"...deidentified data on 110,303 manuscript submissions over 5 years at Science and Science Advances." Key results: - Editors rejected 28.1% of submissions outright. - They sent the other submissions to an advisory board for feedback, and then rejected 75% of those. - If a paper makes it to peer review, then it will be accepted about one-third of the time. - Submissions from "more prestigious" schools are far more likely to make it past the editor. The benefit of being from a prestigious school goes down once the paper makes it to peer review. - Submissions from China are penalized (less likely to be accepted). Papers with lots of authors also have higher success rates. Note that all of these things are correlations, though; it is possible that papers from China are literally just worse on average, or that papers with large teams really are better, etc. - And they made the data available!
8
28
5
215
28,952
We recently launched an essay competition for which scientists described structural problems they run into. With nearly 200 submissions, we decided to give out 8 awards, instead of 3. A quick summary here 👇 1 / 5
3
32
13
148
65,283
Great to see innovation in publishing! Thoughtful progress by Editor in Chief of @BiologyOpen @gorelicklab
Paying peer reviewers led to faster first editorial decisions — an average of 5.5 working days, down from nearly 38 for unpaid reviews. The review quality, as judged by handling editors on the basis of helpfulness in making an editorial decision, went up. 1/
3
20
4,112
Two Presidents of @BCMhouston! Excited to welcome Jakub Tolar as our new President and CEO! He brings enormous energy and enthusiasm to take BCM into the next era, bringing deep experience leading a learning health system and his own interests in clinical translation of basic discoveries. Also grateful for the 16-year leadership of Paul E Klotman, who brought us through financial challenges, the pandemic, and a changing academic landscape with calm and humor. He modernized medical education, our infrastructure, and bolstered our finances; we grew and evolved. We are in a fantastic position for the future. Hope to be recruiting soon- watch this space!
1
3
33
2,293
Amazing paper showing somatic mutations and massive clonal selection for lymphocytes that drive autoimmune disease. Autoimmune diseases are varied and individually relatively uncommon but as a group highly prevalent. These cause lots of morbidity to very many people, with huge personal, societal, and economic impact. If these findings are extended to other autoimmune conditions, they will have huge implications for treatment. Lots in this paper - somatic evolution, new tech, old theories, mutations in your favorite genes... The thread is a great TL;DR for the paper. Go deep and read the cited 2007 Goodnow paper (post#6) - amazingly detailed and prescient- from ~20 years ago!
Excited to share our latest work. Applying advanced single-molecule and single-cell DNA sequencing methods, we uncover an extraordinary landscape of somatic mutations in immune checkpoint genes in autoimmune lymphocytes. [1/n] rdcu.be/fdqbr
2
8
43
8,403
Data on factors impacting time-to-acceptance could be crowd-sourced. Major factors: - time before first editor desk decision (varies a lot by editor and journal) - review time (huge variation; also heavily influenced by the editors) - editor decision time after reviews come in (can be longer than one would think) – revision time (authors chasing very time-consuming experiments for the win; heavily influenced by (lack of) editor guidance, but also topic, model system...) - second round (all same variables) - possible appeal time (appeals are high at top journals and take even more time and can add to total time) Journals track all this data. Authors should have it too. Decent crowd-sourced data could be in ~real-time, and would help authors make informed decisions. I think many ppl would contribute data from their experience.
Monthly median Received to Accepted time (days) at Nature Genetics
2
16
2,306
Great visit with an inspiring group of hematologists! 🙏
👉👉👉Wonderful Visiting Professor Day today with Dr Peggy Goodell .@Goodell_Lab 🙏 for spending time with us at @UTMDAnderson Hematology Grand Rounds hosted by Dr @garciamanero & @doctorpemm | #leusm #endcancer | @sanamloghavi @DrKTakahashi @NitinJainMD @Daver_Leukemia |
3
31
2,948
Exciting new study demonstrating durable DNA methylation reprogramming (editing) in hematopoiesis!
❓A one-time, durable, and even reversible way to prevent thrombosis? In this preprint, led by @lrbzldz, we show that epigenome editing of 🩸 #StemCells can durably reprogram platelet function: biorxiv.org/content/10.64898…
6
35
5,549
Peggy Goodell retweeted
First (to my knowledge) manuscript describing a correlation between number of infections and incidence of clonal hematopoiesis (CHIP). Really important from the perspective of highlighting a possible modifiable driver of CHIP during aging. @ISEHSociety exphem.org/article/S0301-472…
15
3
54
6,705
Remarkable new study showing that many individuals with genetic variants that disrupt the function of myostatin (a protein that normally inhibits muscle growth) have ⬆️muscle mass,⬇️ body fat, and ⬆️strength. Increased muscle mass is clinically desirable for #healthyaging and for countering muscle loss in various contexts (including use of #GLP1 agonists). Below, MRI images of a subject with above-average muscle mass (left) and average muscle mass (right) from the study. Congrats @davidjglassMD and colleagues! Link ⬇️
1
1
16
1,554
It’s also a testament to the incredible societal value of these huge biobanks, the careful genotyping, thoughtful phenotyping, and mechanisms to make these available for analysis. THANK YOU to everyone who participates as a subject, to all the researchers who have worked so hard on these incredibly valuable resources, and to the funding bodies with foresight to invest in these. UKB and similar are truly transformative IMO.
1
233
An interesting question not addressed is the lifestyle differences of people with inactivating myostatin variants. You might guess that people with more muscle will excel in activities where those traits are valuable (e.g., athletics or certain jobs). Those activities might be self-reinforcing, further enhancing muscle growth and amplifying the apparent genetic effect over time. Lots more to learn, but a great investigation that will move the field forward. #aging #muscle #health
211
Important work w real translational potential for cancer patients. Built on foundational science developed over years. Congrats to all!
1
1
21
2,248
Somatic genomics as a discovery engine for biomedicine - a Perspective in Cell sciencedirect.com/science/ar…
12
42
4,161
Amazing new findings on clonal evolution by @jrblundell and team. #dnamethylation barcode for clonal collapse.
Replying to @jrblundell
The methylation patterns at this locus are highly diverse, but once established they are faithfully inherited through cell division. Every clone has its own epigenetic signature. In polyclonal tissue you see a rich, stable rainbow of diversity. When a clone expands, it takes over
1
4
26
5,139
📢 Our review on clonal hematopoiesis + evolutionary dynamics using mathematics is now available online @NatureGenet Check it out! #CHIPsm
Modeling the evolutionary dynamics of clonal hematopoiesis -- @S_Marzban et al, Nature Genetics rdcu.be/e4cP1
3
11
39
4,248